Calendario›REGN›Pozelimab · VIENNA

Pozelimab · VIENNA

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Ensayo de REGENERON PHARMACEUTICALS, INC. en Geographic Atrophy (GA) (del registro, en inglés).

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

54

previstos

Centros

9

Fin del objetivo primario

jul 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en ene 2026.

Qué mide

Occurrence of ocular Treatment-Emergent Adverse Event (TEAEs) in the study eye (Through week 8) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07230834), actualizada en ago 2026.